Search


FDA approves LEMBAZ for infantile-onset NPC: what the news means for Australia
The U.S. FDA has approved LEMBAZ™ (adrabetadex) for eligible people with infantile-onset Niemann–Pick disease type C. The decision marks a milestone for a treatment with a long Australian history: local families and advocates helped bring its clinical trial to Australia. Australian approval and availability have not been confirmed.

ANPDF
2 hours ago3 min read
